Novo Nordisk
NVO
283 Followers
6 August
Upcoming Earnings
Market Cap.
P/E
NVO Fair Price
$30.01
Fair Price Index
The fair price of a share represents the true value of the company's share based on its financial condition and performance. Unlike the current market price, which can fluctuate depending on the mood of the market, the fair price provides us with a better understanding of whether the share is truly advantageous.
Undervalued by 00.8%
To display the fair price of a share, you need to be a member of Bulios Black.
My Notes
Začít psátProfile
Feed
Read More
In the past month alone, $NVOstock is down more than 11%, and according to the Bulios Fair Price Index, the stock is currently slightly undervalued. Recently @edin_medinmentioned this stock , and frankly I'm starting to think about buying it too. If $NVO stock were to drop another 5, 6%, I would buy.
Are you buying $NVOstock on the current decline?
Zobrazit další komentáře
Currently the price is quite low and the price has fallen quite a bit recently, so this could be an interesting opportunity to establish a position.
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
5M
Read More
I recently dissected $NVOhere . I decided to buy shares of this company ahead of its earnings. However, this investment did not work out as I expected. After the mediocre results and the US election results, the stock price rose to $116, however, after a short time it plummeted down to $106. Personally, I expected the price to stay at least at the $110 level, which is where I...
Read more
Zobrazit další komentáře
I haven't purchased, but it's a great company from Europe that I think still has a lot of potential with ASML.
Read More
The anti-obesity drug industry was in 2023 valued at $5.6 billion and will exhibit a CAGR of 27% between 2024 and 2032 (expert opinion).
$LLY, $NVO and others are creating drugs like - Ozempic, Wegovy, Mounjaro and Zepbound - These are blockbusters in terms of weight loss market in my opinion. But which companies may have the best chance to take the biggest bite of that...
Read more
Zobrazit další komentáře
For me ro are both great companies. I wouldn't be afraid to include them in my portfolio. At what price would you buy $LLY?
Read More
📆 Overview of interesting things for the upcoming week! 🚀
This week I will be watching mostly company results. With the investor sentiment from last week, I think wonders will happen when the markets announce earnings.
🔍 Monday:
ISM Services PMI - This index measures economic activity in the service sector and often serves as an indicator of overall economic health.
Earnings: Befor...
Read more
Zobrazit další komentáře
Thanks again for the summary, great! The results will certainly be interesting, but more so in the long run. They can't change the market situation this week in my opinion.
Read More
Analysts at Berenberg have raised their estimates for the global obesity market to $150 billion by 2035, up from $125 billion previously. This revision is the result of positive data on co-morbidities and advances in competing studies. Berenberg recommends buying shares of $LLY and Zealand Pharma, while he recommends holding on to shares of $NVO.
What are your thoughts on...
Read more
Zobrazit další komentáře
This sector currently has great potential. However, shares in this sector are already quite expensive. I bought $NVO and I don't regret it.
Read More
📊 Investment Calendar 📆
Earnings season is in full swing, and with it comes more exciting news. Here is a summary of the news I will be following.
Monday: I'll only be watching company results.
📈 Earnings: Before the markets open, I'll be watching Domino's Pizza $DPZ, SoFi Technologies $SOFI and ON Semiconductor $ON. After the close, just the results of Paramount $PARA and Logit...
Read more
Read More
📈💡 New and interesting player on the pharmaceutical market! 💊🔍
One of the most discussed topics in the pharmaceutical market is the treatment of obesity and diabetes. Only two companies are behind many successful drugs such asOzempic, Rybelsus and Saxenda: Novo Nordisk $NVO and Eli Lilly $LLY. These companies have had significant success in the treatment of diabetes and...
Read more
Read More
Novo Nordisk A/S is a Danish company that recently introduced a cure for obesity. Shares of $NVO are up more than 20% in the past month and more than 40% this year. For me, the company is going in a good direction and the business is also great, as obesity is really affecting a lot of people at the moment and if the development of this drug goes as well in the future as it has...
Read more
Zobrazit další komentáře
The company is doing very well indeed. It's healthy and making solid amounts of money. The chart is logically consistent with that. But now I think it's way up and even though there's no major tooth on the chart, I'm not going to go for it.
Zobrazit další komentáře
I don't have NVO stock in my portfolio, but I am very interested in the company and have been following it from afar :)
The company is doing well, but I wouldn't buy the stock as it's a pretty volatile and choppy business. You can see it just on this news alone that one drug will fail and the stock will plummet 20%. I think that's terrible.